Minocin is a drug owned by Rempex Pharmaceuticals Inc A Wholly Owned Sub Of Melinta Therapeutics Llc. It is protected by 3 US drug patents filed from 2015 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2032. Details of Minocin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11944634 | Tetracycline compositions |
Oct, 2032
(7 years from now) | Active |
| US9084802 | Tetracycline compositions |
May, 2031
(6 years from now) | Active |
| US9278105 | Tetracycline compositions |
May, 2031
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Minocin's patents.
Latest Legal Activities on Minocin's Patents
Given below is the list of recent legal activities going on the following patents of Minocin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 11 Jun, 2024 | US11944634 |
| Email Notification Critical | 11 Jun, 2024 | US11944634 |
| Mail Patent eCofC Notification | 11 Jun, 2024 | US11944634 |
| Patent eCofC Notification | 11 Jun, 2024 | US11944634 |
| Email Notification Critical | 30 Apr, 2024 | US11944634 |
| Mail Patent eCofC Notification | 30 Apr, 2024 | US11944634 |
| Recordation of Patent eCertificate of Correction | 30 Apr, 2024 | US11944634 |
| Patent eCofC Notification | 30 Apr, 2024 | US11944634 |
| Post Issue Communication - Certificate of Correction | 09 Apr, 2024 | US11944634 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944634 |
US patents provide insights into the exclusivity only within the United States, but Minocin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Minocin's family patents as well as insights into ongoing legal events on those patents.
Minocin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Minocin's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 16, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Minocin Generic API suppliers:
Minocycline Hydrochloride is the generic name for the brand Minocin. 26 different companies have already filed for the generic of Minocin, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Minocin's generic
How can I launch a generic of Minocin before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Minocin's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Minocin's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Minocin -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100 mg/vial | 16 Oct, 2020 | 1 | 22 Jul, 2022 | 12 May, 2031 | Eligible |
Alternative Brands for Minocin
Minocin which is used for treating bacterial infections., has several other brand drugs in the same treatment category and using the same active ingredient (Minocycline Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
| Xellia Pharms Aps |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Minocycline Hydrochloride. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Minocycline Hydrochloride, Minocin's active ingredient. Check the complete list of approved generic manufacturers for Minocin
About Minocin
Minocin is a drug owned by Rempex Pharmaceuticals Inc A Wholly Owned Sub Of Melinta Therapeutics Llc. It is used for treating bacterial infections. Minocin uses Minocycline Hydrochloride as an active ingredient. Minocin was launched by Rempex in 1982.
Approval Date:
Minocin was approved by FDA for market use on 01 January, 1982.
Active Ingredient:
Minocin uses Minocycline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Minocycline Hydrochloride ingredient
Treatment:
Minocin is used for treating bacterial infections.
Dosage:
Minocin is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE/VIAL | INJECTABLE | Prescription | INJECTION |